The KRASG12D Inhibitor Pipeline Grows.

Abstract excerpt

At this year's ASCO Annual Meeting, investigators also presented encouraging early clinical data for several KRASG12D-selective inhibitors, including RNK08594, GFH375, and DN022150, suggesting that this type of drug could play a role in the treatment of several solid tumors, such as pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Mutation
• Share to Pancreatic Neoplasms
• Share to Protein Kinase Inhibitors